Get the tools used by (smart)2 investors.

Inozyme Pharma IncNASDAQGS:INZY

United States / Healthcare / Biotechnology

Income Statement
Balance Sheet
Cash Flow Statement
EBITDA Reconciliation
Net Income Reconciliation
Forecasts
Valuation Ratios
Fiscal Years
Fiscal Half
Fiscal Quarters
Year To Date
Latest Twelve Months
Ascending
Descending
3 Years
5 Years
10 Years
Millions
Billions
Thousands
Ones
Standard Size
Common Size
Growth Rate
2019-12-31
FY-4
2020-12-31
FY-3
2021-12-31
FY-2
2022-12-31
FY-1
2023-12-31
FY
Revenue
-
-
-
-
-
Revenue Growth (YoY)
NM
NM
NM
NM
NM
Cost of Revenues
0.0
0.0
0.0
0.0
0.0
Gross Profit
-
-
-
-
-
Gross Profit Margin
-
-
-
-
-
R&D Expenses
-19.6
-18.0
-25.2
-42.2
-65.2
Selling and Marketing Expense
0.0
0.0
0.0
0.0
0.0
General & Admin Expenses
-4.5
-4.2
-10.1
-18.1
-19.8
Other Inc / (Exp)
-0.1
0.0
0.0
-0.3
0.1
Operating Expenses
-24.2
-22.2
-35.3
-60.6
-84.9
Operating Income
-24.2
-22.2
-35.3
-60.6
-84.9
Net Interest Expenses
0.0
0.0
0.0
1.9
8.6
EBT, Incl. Unusual Items
-24.2
-22.2
-35.3
-58.8
-76.3
Earnings of Discontinued Ops.
-
-
-
-
-
Income Tax Expense
0.0
0.0
0.0
0.0
-0.1
Net Income to Company
-24.2
-22.2
-35.3
-58.8
-76.4
Minority Interest in Earnings
-
-
-
-
-
Net Income to Stockholders
-24.2
-22.2
-35.3
-58.8
-76.4
Preferred Dividends & Other Adj.
-6.0
-7.9
-10.9
0.0
0.0
Net Income to Common Excl Extra Items
-30.2
-30.1
-46.2
-58.8
-76.4
Basic EPS (Cont. Ops)
-89.35
-82.06
-8.95
-1.96
-1.93
Diluted EPS (Cont. Ops)
-89.35
-82.06
-8.95
-1.96
-1.93
Weighted Average Basic Shares Out.
0.3
0.4
5.2
29.9
39.6
Weighted Average Diluted Shares Out.
0.3
0.4
5.2
29.9
39.6
EBITDA
-23.6
-21.4
-34.4
-59.1
-83.7
EBIT
-24.1
-22.2
-35.3
-60.3
-85.0
Revenue (Reported)
-
-
-
-
-
Operating Income (Reported)
-24.1
-22.2
-35.3
-60.3
-85.0
Operating Income (Adjusted)
-24.1
-22.2
-35.3
-60.3
-85.0
FY-4FY-3FY-2FY-1FY01234
presentment in Millions except per share data. All rights reserved. Terms Of Use